Dr Jennifer David discusses the use of cysteamine 5% as a novel first line non‑hydroquinone treatment option bridging that gap between safety and efficacy in treating hyperpigmentation Disorders of hyperpigmentation,

This content is restricted to site members. If you are an existing user, please log in. New users may register below.

Existing Users Log In